The Unichem Laboratories share price touched a 52-week high of Rs 479.25 at noon on January 11 after the company received United States Food and Drug Administration's nod for the generic version of a hypertension drug.
At 12.04 am, Unichem Laboratories was quoting at Rs 479.10, up Rs 33.60, or 7.54 percent, on the BSE.
"...... has received ANDA approval for its Doxazosin Tablets USP, 1 mg, 2 mg, 4 mg and 8 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Cardura (Doxazosin) Tablets, 1 mg, 2 mg, 4 mg and 8 mg, of Viatris Specialty, LLC," company said.
Doxazosin is indicated for the treatment of hypertension to lower blood pressure.
The product will be commercialised from the company's Goa plant.
Catch all market action in our live blog
In December, the company again sold shares held in Optimus Drugs to Sekhmet Pharmaventures for Rs 67.47 crore in a second tranche of divestment in the pharma firm. In May 2022, Unichem sold 19.97 percent of equity in Optimus to Sekhmet Pharmaventures.
Unichem has several pharma products in therapeutic areas like gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management, the company said.
Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
